

1        **A nanobody toolbox to investigate localisation and dynamics of *Drosophila* titins**

2

3        Vincent Loreau<sup>1</sup>, Renate Rees<sup>2</sup>, Eunice HoYee Chan<sup>1</sup>, Waltraud Taxer<sup>2</sup>, Kathrin Gregor<sup>2</sup>,

4        Bianka Mußil<sup>2</sup>, Christophe Pitaval<sup>1</sup>, Nuno Miguel Luis<sup>1</sup>, Pierre Mangeol<sup>1</sup>, Frank Schnorrer<sup>1</sup>,

5        Dirk Görlich<sup>2</sup>

6

7        <sup>1</sup>Aix Marseille University, CNRS, IBDM, Turing Centre for Living Systems, 13288

8        Marseille, France

9        <sup>2</sup>Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany

10

11

12        Correspondence:

13        [frank.schnorrer@univ-amu.fr](mailto:frank.schnorrer@univ-amu.fr)

14        [goerlich@mpinat.mpg.de](mailto:goerlich@mpinat.mpg.de)

15

16        keywords: nanobodies; titin; muscle; sarcomere; myofibril; *Drosophila*; FRAP;

17

18

19 **Abstract:**

20 **Measuring the positions and dynamics of proteins in intact tissues or whole animals is**  
21 **key to understand protein function. However, to date this is still a challenging task, as**  
22 **accessibility of large antibodies to dense tissues is often limited and fluorescent proteins**  
23 **inserted close to a domain of interest may affect function of the tagged protein. These**  
24 **complications are particularly present in the muscle sarcomere, arguably one of the**  
25 **most protein dense structures in nature, which makes studying morphogenesis at**  
26 **molecular resolution challenging. Here, we have employed an efficient pipeline to**  
27 **generate a nanobody toolbox specifically recognising various domains of two large**  
28 ***Drosophila* titin homologs, Sallimus and Projectin. We demonstrate the superior**  
29 **labelling qualities of our nanobodies compared to conventional antibodies in intact**  
30 **muscle tissue. Applying our nanobody toolbox to larval muscles revealed a gigantic**  
31 **Sallimus isoform stretched more than 2  $\mu$ m to bridge the sarcomeric I-band.**  
32 **Furthermore, N- and C-terminal nanobodies against Projectin identified an unexpected**  
33 **polar orientation of Projectin covering the myosin filaments in larval muscles. Finally,**  
34 **expression of a Sallimus nanobody in living larval muscles confirmed the high affinity**  
35 **binding of nanobodies to target epitopes in living tissue and hence demonstrated their**  
36 **power to reveal the *in vivo* dynamics of sarcomeric protein domains. Together, our**  
37 **toolbox substantiates the multiple advantages of nanobodies to study sarcomere biology.**  
38 **It may inspire the generation of similar toolboxes for other large protein complexes in**  
39 ***Drosophila* or mammals.**

40

41

42

### 43     Introduction

44     Muscles use their sarcomeres to generate forces that power animal movements. The  
45     sarcomere morphologies are remarkably conserved from fruit flies to humans: each sarcomere  
46     is bordered by two Z-discs that cross-link the plus-ends of parallel actin filaments, while their  
47     minus ends face towards the centrally located bipolar myosin filaments (Lange et al., 2006;  
48     Lemke and Schnorrer, 2017). Both filaments are stably linked by the gigantic titin spring  
49     protein, which in mammals binds with its N-terminus to alpha-actinin at the Z-disc and is  
50     anchored with its C-terminus at the M-band in the middle of the sarcomere. Such, titin  
51     determines the length of the mammalian sarcomere (Linke, 2018; Luis and Schnorrer, 2021;  
52     Tskhovrebova and Trinick, 2003).

53         As muscle and in particular sarcomere architecture is well-conserved, *Drosophila* is a  
54     fantastic model to study how a sarcomere is built during development (Katzemich et al., 2013;  
55     2015; Orfanos et al., 2015; Weitkunat et al., 2017; 2014). Generation of monoclonal  
56     antibodies against *Drosophila* sarcomere proteins have been insightful to locate key proteins  
57     within the mature sarcomere (Burkart et al., 2007; Ferguson et al., 1994; Katzemich et al.,  
58     2012; Lakey et al., 1990; Qiu et al., 2005; Szikora et al., 2020). However, a systematic  
59     toolbox of antibodies recognising defined domains of the often large sarcomeric proteins, in  
60     particular against defined domains of the two large *Drosophila* titin homologs Sallimus (Sls)  
61     and Projectin (gene called *bent*, *bt*) is still missing. These tools would be important to  
62     understand how the sarcomeric machine assembles during muscle morphogenesis.

63         Recent gene tagging approaches have generated a substantial amount of *Drosophila*  
64     transgenic lines, each expressing one sarcomeric protein fused to GFP at its C-terminus  
65     (Sarov et al., 2016) or at a random internal position (Buszczak et al., 2007; Kanca et al., 2017;  
66     Kelso et al., 2004; Nagarkar-Jaiswal et al., 2015). Nevertheless, a number of these tagged  
67     lines label only a subset of protein isoforms or result in homozygous loss of function  
68     phenotypes as the GFP tagged protein cannot fully recapitulate the function of the

69 endogenous protein in the dense sarcomeric environment (Orfanos and Sparrow, 2013;  
70 Orfanos et al., 2015; Sarov et al., 2016). Hence, classical GFP tagging does not always  
71 provide an optimal solution to study the native dynamics of a sarcomeric protein.

72 These limitations motivated us to develop a complementary toolbox to antibodies and  
73 GFP-tagged lines for sarcomeric proteins that will be particularly well suited for the dense  
74 environment of mature sarcomeres in intact muscles (O'Donnell et al., 1989). We chose the  
75 recent cameloid nanobody technology, because of the small size of nanobodies (<4 nm, 12-  
76 15 kDa), their single chain protein nature and their high-affinity against target domains  
77 (Muyllemans, 2013; Pleiner et al., 2018; 2015). As nanobodies can be used on fixed samples  
78 or fused to a fluorescent protein and expressed in living tissues, nanobodies are ideal tools to  
79 quantify the position and dynamics of sarcomeric proteins in their dense environment.

80 Thus far, the application of nanobodies to the *Drosophila* model was largely restricted  
81 to commercially available GFP and mCherry nanobodies that allowed to locate, trap or  
82 degrade GFP- or mCherry-tagged proteins in *Drosophila* tissue (Ákos et al., 2021; Caussinus  
83 et al., 2011; Harmansa and Affolter, 2018; Harmansa et al., 2017; 2015). Recently,  
84 nanobodies located *Drosophila* proteins tagged with short artificial nanotags (Xu et al., 2022).  
85 However, prior to our studies nanobodies binding to endogenous *Drosophila* protein domains  
86 had to our knowledge not yet been made.

87 Here we generated a nanobody toolbox against seven different epitopes of the two  
88 *Drosophila* titin homologs Sallimus (Sls) and Projectin (Proj). After recombinant expression  
89 and labelling, we verified their specificity as well as their superior penetration and labelling  
90 efficiencies compared to antibodies. Applying our nanobodies to *Drosophila* muscle tissues  
91 confirmed the expression of different Sls isoforms in different muscle types and identified a  
92 gigantic more than 2 µm long Sls protein in larval muscles. It further revealed that Projectin is  
93 bound to the myosin filament in a strictly polar fashion, resembling the mammalian titin  
94 homolog. Finally, by generating transgenic animals expressing nanobody-Neongreen fusions,

95 we verified that nanobodies are suitable tools to monitor the dynamics of endogenous  
96 sarcomeric proteins in intact living animals.

97

98

99 **Results**

100 ***Drosophila* titin nanobody design**

101 Mammalian sarcomere length is determined by a long titin protein isoform that spans linearly  
102 from the Z-disc to the M-band and thus adopts a length of about 1.5  $\mu$ m in relaxed human  
103 muscle (Brynnel et al., 2018; Fürst et al., 1988; Linke, 2018). In order to investigate to what  
104 extend the localisation of this critical sarcomere component is conserved across evolution of  
105 bilaterian muscle, we aimed to re-investigate the localisation of the two *Drosophila* titin  
106 homologs Sallimus and Projectin by generating specific nanobodies. By carefully mining the  
107 Flybase expression database (<http://flybase.org/reports/FBgn0086906>;  
108 <http://flybase.org/reports/FBgn0005666>) we have annotated the likely longest Sallimus (Sls)  
109 and Projectin (Proj, gene called *bent*, *bt*) isoforms expressed in larval body wall muscles  
110 (Figure 1A, B). The longest Sls isoform contains 48 immunoglobulin (Ig)-domains of the total  
111 52 Ig domains coded in the Sls gene (4 are selectively present in a short larval isoform).  
112 Additionally, Sls does contain long stretches of flexible regions rich in amino acids proline,  
113 valine, glutamic acid and lysine (PEVK) that form an elastic spring and five C-terminal  
114 fibronectin (Fn)-domains (Figure 1A) (Burkart et al., 2007). This domain organisation largely  
115 resembles the I-band part of mammalian titin (Tskhovrebova and Trinick, 2003).

116 Conversely, the long Projectin isoform contains 35 Ig- and 39 Fn-domains that are  
117 mainly organised in Ig-Fn super-repeats with a consensus myosin light chain kinase domain  
118 close to its C-terminus (Figure 1B) (Ayme-Southgate et al., 2008). This domain organisation  
119 largely resembles the A-band part of mammalian titin (Tskhovrebova and Trinick, 2003).

120 To generate nanobodies against Sls and Proj domains, we selected a subset of small  
121 domains that according to published transcriptomics data (Spletter et al., 2015; 2018) should  
122 also be expressed in other muscle types, such as flight or leg muscles. We chose domains  
123 close to the N- and C-termini of both proteins to assess their possible extended configuration  
124 in sarcomeres. We successfully expressed Sls-Ig13/14, Sls-Ig49/50 and SlsIg51/52  
125 recombinantly and generated the respective nanobodies Sls-Nano2, Sls-Nano39, Sls-Nano42  
126 and Sls-Nano48 against these domains (Figure 1A). For Projectin we selected Ig5-8, Fn1/2,  
127 Ig27-Fn35 as well as the kinase domain to generate Projectin nanobodies Proj-Nano30, Proj-  
128 Nano28 and 29, Proj-Nano33, and Proj-Nano34, 35, 37 and 46 recognising these domains,  
129 respectively (Figure 1B).

130

131 ***Drosophila* titin nanobody production**

132 To effectively produce a comprehensive set of nanobodies against the above selected Sls and  
133 Proj domains, we used two sources of immunogens (Figure 2 for workflow). First, we hand-  
134 dissected the indirect flight muscles from 1000 wild-type adult flies and isolated their  
135 myofibrils, which express large amounts of Sls and Proj (Spletter et al., 2018). These were  
136 used for two immunisations of the alpaca. Second, we recombinantly expressed selected Sls  
137 and Proj domains as His<sub>14</sub>-SUMO or His<sub>14</sub>-NEDD8-tagged proteins in *E.coli* and purified  
138 them by binding to a Ni(II) chelate matrix, followed by extensive washing and elution with a  
139 tag-cleaving protease (Frey and Görlich, 2014a). These recombinant antigens (100 µg each)  
140 were used for three consecutive immunisations. Four days after the last immunisation, a blood  
141 sample was taken, lymphocytes were recovered, total RNA was isolated and reverse  
142 transcribed into cDNA. Finally, a phage display library with a complexity of more than 10<sup>8</sup>  
143 independent clones was constructed. This followed a previously described workflow (Pleiner  
144 et al., 2015; 2018).

145 To isolate high-affinity nanobodies, we employed three rounds of phage display, using  
146 low concentrations (1nM) of baits. Coding sequences of selected nanobodies were sequenced  
147 in a 96-well format and classified according to their sequence similarity. Selected clones were  
148 then expressed as His<sub>14</sub>-SUMO-tagged fusions in *E.coli* and purified by the affinity-capture-  
149 protease elution strategy, with typical yields of 20-50 mg nanobody per litre TB culture.

150

151 **Nanobody labelling and affinities**

152 For application in fluorescence microscopy, we labelled the nanobodies directly through one  
153 or two ectopic cysteines (N- and C-terminal) with appropriate maleimides (Pleiner et al., 2015;  
154 2018). The labelling was performed "on-column", i.e., after binding the His<sub>14</sub>-SUMO-tagged  
155 nanobodies to Ni(II) chelate beads. Washing of the beads allowed for convenient removal of  
156 free fluorophore before the tag-free labelled nanobodies were eluted with the tag-cleaving  
157 protease. The labelling according to this workflow was nearly quantitative, as indicated by the  
158 observed size shifts on SDS-PAGE (Figure 3A) and by a ratiometric measurement of the  
159 optical densities at the absorption maxima of protein and the fluorophore.

160 To measure the binding affinity ( $K_D$ ) of a nanobody to its target, we chose Sls-Nano2,  
161 labelled it with biotin, and immobilised it on high-precision streptavidin Octet sensors for  
162 biolayer interferometry (Figure 3B). On- and off-rates of the cognate Sls Ig13/14 domains  
163 were then measured by allowing a concentration series to bind and subsequently to dissociate  
164 from the nanobody (Figure 3B). The data indicate a nearly irreversible binding with an on-  
165 rate of  $\sim 10^6 \cdot M^{-1} \cdot sec^{-1}$ , an off-rate in the order of  $10^{-5} \cdot M^{-1} \cdot sec^{-1}$  and  $K_D$  in the 10 pM range.  
166 Note that such high affinity is already at the limit of what can be reliably measured with this  
167 technology. Such a high affinity can be explained by *Drosophila* proteins being highly  
168 immunogenic in mammals, by the very large immune repertoire of alpacas, and by our very  
169 stringent selection from a very large immune library.

170

171 **Sallimus and Projectin nanobody specificity**

172 To assess the efficiency and specificity of our nanobodies in muscle tissue we first assayed  
173 how well they label late stage *Drosophila* embryonic muscles. We fixed wild type stage 17  
174 embryos and incubated them with fluorescently labelled Sls or Proj nanobodies and  
175 performed confocal microscopy. We found that most of our nanobodies, which had passed  
176 our selection criteria (see Methods), efficiently stained embryonic muscles revealing the  
177 expected striated pattern of Sls and Proj in stage 17 embryos (Figure 4A, B and Figure 4  
178 supplements 1 and 2). Thus, in total we generated 12 different Sls and Proj nanobodies  
179 against 3 different Sls and 4 different Proj epitopes.

180 To test for the specificity of the nanobodies we generated embryos in which we either  
181 depleted the Sls or Proj protein by muscle-specific RNAi using *Mef2-GAL4* (Schnorrer et al.,  
182 2010), followed by a double staining with anti-Sls and anti-Proj nanobodies. Importantly, we  
183 found that in all cases the staining of Sls or Proj was severely reduced or lost entirely after  
184 knock-down of the respective protein, demonstrating the specificity of our nanobodies (Figure  
185 4 and Figure 4 supplements 1 and 2). As expected, in each case we found that the striated  
186 pattern of the other protein was lost, demonstrating that both, Sls and Proj are required to  
187 generate striated sarcomeres in stage 17 embryos. We conclude that our nanobodies  
188 specifically recognise the various Sls and Proj domains against which they were raised and  
189 hence should be valuable tools to study the roles of the *Drosophila* titin homologs in  
190 sarcomere biology.

191

192 **Nanobodies display superior labelling and penetration efficiencies**

193 Nanobodies are attractive labels because of their small size compared to conventional  
194 antibodies. We wanted to investigate if this proposed theoretical advantage matters in practice  
195 when staining *Drosophila* muscle samples. We compared the labelling of our nanobodies to  
196 conventional antibodies visualised with standard secondary antibodies in embryos at stage 16

197 and stage 17. The rational being that at stage 17, the future larval cuticle is already deposited  
198 around the embryos (Moussian, 2010), hindering the penetration of large labels into the  
199 embryos and thus rendering the staining ineffective when compared with stage 16. We used  
200 the nanobodies against Sls and Proj together with either Sls, myosin heavy chain (Mhc) or  
201 Proj antibodies (Figure 5A-C). In stage 16 embryos we found the expected co-localisation of  
202 Sls-Nano2, recognising Sls-Ig13/14, with an anti-Sls antibody, recognising Sls-Ig16 (called  
203 anti-Kettin) (Kulke et al., 2001) (Figure 5A), as well as the co-localisation of Proj-Nano30  
204 recognising Proj-Ig5-8 with a Proj antibody (Figure 5C). Both Sls and Proj proteins are not  
205 yet displaying a striated pattern as sarcomeres have not yet assembled at stage 16.

206 Strikingly, while our nanobodies stained the body muscles of stage 17 embryos very  
207 well, displaying the striated pattern of the first formed sarcomeres, neither Kettin, Mhc nor  
208 Projectin antibodies produced a good staining pattern (Figure 5A-C). This demonstrates the  
209 superior penetration and labelling efficiency of small nanobodies compared to antibodies. We  
210 found similar differences when testing penetration efficiencies in large flight muscles in the  
211 accompanying manuscript (Schueder et al., 2022). Together, we conclude that the here  
212 generated Sls or Proj nanobody toolbox specifically recognises Sls or Proj domains, which  
213 allows efficient labelling of sarcomeres in whole mount late-stage embryos, i.e. at a stage that  
214 is impossible to investigate with antibodies following standard protocols.

215

## 216 **Sallimus and Projectin localisation in mature muscles**

217 Our Sls and Proj toolbox should be highly valuable to investigate muscle development at  
218 various stages of the *Drosophila* life cycle as we had chosen Sls and Proj domains that are  
219 predicted to be expressed in most muscle types at most stages of development (see Figure 1).  
220 To test this prediction, we next investigated adult *Drosophila* flight muscles, which show a  
221 specialised fibrillar morphology of their myofibrils and sarcomeres that is caused by the  
222 expression of a specific combination of sarcomeric protein isoforms (Schönbauer et al., 2011;

223 Spletter et al., 2015). Co-staining flight muscles with the Sls-Nano2 recognising Sls-Ig13/14  
224 close to the N-term of Sls and Sls-Nano42 recognising Sls-Ig51-Fn2 close to the C-term of  
225 Sls revealed single and overlapping bands present at the sarcomeric Z-disc (Figure 6A). This  
226 pattern is expected since flight muscles contain a very short about 100 nm wide I-band  
227 (Burkart et al., 2007). The Sls-Nano42 band is shorter, with a smaller cross-sectional radius  
228 compared to Sls-Nano2 suggesting that Sls-Ig51-Fn2 is not present in all the Sls isoforms  
229 expressed during the final stages of myofibril maturation that complete radial myofibril  
230 growth (González-Morales et al., 2019; Spletter et al., 2018). Such a central localisation of the  
231 long Sls isoforms in flight muscle sarcomeres had also been reported previously with the anti-  
232 Sls antibody B2 that likely recognises Sls-Ig36-41 domains (Burkart et al., 2007), thus further  
233 confirming the specificity of our domain-specific Sls nanobodies.

234 Next, we investigated the localisation of Proj in flight muscles and found the N-  
235 terminal Ig5-8 recognised by Proj-Nano30 resulted in a single band overlapping with the Z-  
236 disc, whereas the Proj-Nano37 recognising the Proj kinase domain at its C-terminal end  
237 resulted in 2 bands right and left of the I-band, likely overlapping with the myosin filament  
238 (Figure 6A). Hence, we verified with our nanobodies that Proj is oriented in a linear fashion  
239 in flight muscles with its N-terminus closer to the Z-disc and its C-terminus facing the myosin  
240 filaments. Quantifying the precise positions of the Sls and Proj domains bound by our  
241 nanobodies in flight muscles requires super-resolution microscopy, which is reported in the  
242 accompanying manuscript (Schueder et al., 2022).

243 In contrast to indirect flight muscles, *Drosophila* leg or larval muscles have longer I-  
244 bands, likely caused by the expression of longer Sls splice isoforms that include large parts of  
245 the flexible PEVK spring domains making these muscles softer (Burkart et al., 2007; Spletter  
246 and Schnorrer, 2014). However, the precise positions of N- and C-terminal ends of Sls in  
247 these muscle types had not been investigated in detail prior to our studies. To address this  
248 open question, we prepared fixed adult hemi-thoraces and third instar (L3) larval filets and

249 stained leg or larval body muscles with the N- and C-terminal Sls nanobodies. We found that  
250 Sls-Nano2 overlaps with the Z-disc in leg and larval muscles, similar to flight muscles.  
251 However, the C-terminal Sls-Nano42 recognising Sls-Ig51-Fn2 revealed 2 distinct bands with  
252 larger distances in larval muscles compared to leg muscles (Figure 6B, C). This demonstrated  
253 that *Drosophila* Sls is extended as a linear molecule bridging from the Z-disc likely to the  
254 myosin filament in sarcomeres with long I-bands.

255 In contrast to its defined location in flight muscles, earlier studies using Projectin  
256 antibodies suggested that Projectin largely decorates the thick filament in *Drosophila* leg  
257 muscles (Lakey et al., 1990; Saide et al., 1989; Vigoreaux et al., 1991). Consistent with these  
258 previous reports, staining of adult leg or larval body muscles with our N- and C-terminal Proj  
259 nanobodies, Proj-Nano30 and Proj-Nano37 respectively, revealed two large blocks, instead of  
260 sharp bands, located on the myosin filament in both adult leg and larval body muscles (Figure  
261 6B, C). When carefully analysing the overlap of Proj-Nano30 and Proj-Nano37 staining, we  
262 surprisingly found that these blocks were slightly shifted in respect to each other. N-terminal  
263 Proj-Nano30 staining located closer towards the Z-disc, whereas the C-terminal Proj-Nano37  
264 staining was closer towards the M-band (Figure 6B, C). These results suggested that Proj  
265 decorates the myosin filament of cross-striated *Drosophila* muscles in a polar fashion.

266

### 267 **Sallimus is stretched across long I-bands**

268 To quantify the precise length of Sls in relaxed larval muscle sarcomeres we measured the  
269 distances between the Sls-Nano2 and Sls-Nano42 peaks. We found that Sls extends over more  
270 than 2  $\mu$ m in relaxed L3 sarcomeres that are about 8.5  $\mu$ m long (Figure 7A). We verified the  
271 Sls length by staining with a second Sls nanobody close to the Sls C-term, Sls-Nano39  
272 recognising Sls-Ig49/50 (Figure 7 supplement 1A). To test if the Sls C-terminus can indeed  
273 reach the beginning of the myosin filament, we co-stained larval muscles with N- and C-  
274 terminal Sls nanobodies together with an Mhc antibody (Figure 7B). Indeed, we found that

275 Sls-Nano42 recognising Sls-Ig51-Fn2 localises to the beginning of the myosin filaments,  
276 demonstrating that each long Sls isoform indeed stretches across the entire long I-band of  
277 larval muscles, likely to mechanically link the Z-discs to the myosin filaments.

278

279 **Projectin is oriented on the thick filament**

280 We wanted to verify our surprising finding that N- and C-terminal Proj nanobodies result in  
281 distinct localisation patterns in sarcomeres of larval muscles. We double stained larval  
282 muscles with additional combinations of N- and C-terminal Proj nanobodies, namely Proj-  
283 Nano28 recognising Proj-Fn1/2 with Proj-Nano34 recognising the Proj kinase domain and  
284 Proj-Nano29 recognising Proj-Fn1/2 combined with Proj-Nano35 also recognising the Proj  
285 kinase domain. Again, we found that both nanobody combinations label two blocks located  
286 on the myosin filament, with Proj-Fn1/2 located closer to the Z-disc and the Proj kinase  
287 domain located closer to the M-band (Figure 7 – supplement 1B, C). Furthermore, we  
288 obtained the same result with a fourth combination of nanobodies, Proj-Nano29 recognising  
289 Proj-Fn1/2 and Proj-Nano33 binding to Proj-Ig27-Fn35 (Figure 7 – supplement 1D). This  
290 ‘shifted-blocks’ pattern is not a technical artefact as double staining with Proj-Nano30 and  
291 Proj-Nano28 or with Proj-Nano35(kinase) and Proj-Nano46(kinase) showed an almost perfect  
292 overlap (Figure 7 – supplement 1E, F). Finally, we confirmed the ‘shifted-blocks’ pattern by  
293 imaging the Proj-Nano30(Ig5-8) and Proj-Nano37(kinase) patterns with an airy-scan detector  
294 that slightly increases the spatial resolution (Figure 7C).

295 We hypothesized that the small central gap visible in the Proj-kinase domain  
296 nanobody patterns is caused by a Projectin-free M-band of the larval sarcomere. Co-labelling  
297 the M-band with Obscurin-GFP, which specifically localises to the M-band (Katzemich et al.,  
298 2012; Sarov et al., 2016), confirmed that the gap present in the Proj-kinase nanobody pattern  
299 is consistent with its absence from the M-band (Figure 7D). Taken together, our results  
300 demonstrate that Projectin decorates the myosin filament in a defined polar orientation, likely

301 from the tip of the myosin filament until the beginning of the H-zone that is devoid of myosin  
302 heads.

303  
304 **Live imaging of Sls using nanobodies *in vivo***

305 Nanobodies have the particular advantage that they are single chain proteins that can be  
306 expressed in the cytoplasm of eukaryotic cells. To our knowledge only nanobodies against  
307 GFP, mCherry or short epitope tags had thus far been expressed in *Drosophila* tissues  
308 (Caussinus et al., 2011; Harmansa and Affolter, 2018; Harmansa et al., 2015; 2017; Xu et al.,  
309 2022). Hence, we wanted to test if our nanobodies are useful tools to track a native sarcomeric  
310 protein in the mature muscle, similar to a direct GFP fusion to the sarcomeric protein. For  
311 proof of principle experiments, we chose Sls-Nano2 for two reasons: first, Sls is likely stably  
312 incorporated into mature sarcomeres and its large size should prevent fast diffusion. Thus, Sls  
313 is a suitable protein to test if a nanobody would be stably bound to a target protein in muscle.  
314 Second, we had verified the high affinity of Sls-Nano2 to the Sls-Ig13/14 target *in vitro*  
315 (Figure 3B).

316 To test how stably Sls-Nano2 binds to Sls *in vivo*, we expressed Sls-Nano2-Neongreen  
317 driven by *Mef2-GAL4* during all stages of muscle development and assayed muscles of intact  
318 living L3 larvae. We found the expected striated pattern of Sls-Nano2-Neongreen (Figure 8A)  
319 resembling the Sls-Nano2 staining in fixed larval muscles. Thus, Sls-Nano2-Neongreen binds  
320 to Sls-Ig13/14 *in vivo*. To quantify the diffusion and local turn-over of Sls-Nano2-Neongreen,  
321 we established a protocol that allowed us to image intact living larvae under the spinning disc  
322 microscope for at least 30 min (see Methods). This enabled us to measure fluorescence  
323 recovery after photobleaching (FRAP) of Sls-Nano2-Neongreen in living larval muscles. We  
324 bleached one area in L3 larval muscles and measured fluorescence recovery over 29 min  
325 (Figure 8A, B, Figure 8 - Video 1). We found little to no recovery during the observation  
326 period. This demonstrates that the Sls-Nano2 is indeed stably bound the Sls-Ig13/14 target

327 and furthermore that Sls protein does not exchange significantly over a 30 min period in  
328 mature larval muscles. Together, these data verified that nanobodies against *Drosophila*  
329 proteins can indeed be expressed *in vivo* and thus can be used to investigate the dynamics of a  
330 chosen target domain. Hence, the here generated nanobodies will be invaluable tools to  
331 quantify the dynamics of Sls and Proj during muscle development and maintenance.

## 332 **Discussion**

### 333 **Nanobodies as tools for developmental biology**

334 Thus far, the application of nanobodies in *Drosophila* was limited to nanobodies against  
335 fluorescent proteins or recently against short epitope tags (Caussinus et al., 2011; Harmansa  
336 and Affolter, 2018; Harmansa et al., 2015; 2017; Xu et al., 2022). These former studies had  
337 shown that nanobodies against GFP can be used to trap secreted Dpp in the *Drosophila* wing  
338 disc, and hence demonstrated the strong binding of nanobodies to their target also *in vivo*  
339 (Harmansa et al., 2015; 2017). Here we demonstrated that the high affinity of nanobodies to  
340 their targets *in vivo* is not limited to the commercially available GFP nanobody that the fly  
341 community has extensively used in the past (Caussinus et al., 2011; Harmansa and Affolter,  
342 2018). It is likely also the case for most of the here presented Sls and Proj nanobody toolbox,  
343 as exemplified in detail for Sls-Nano2. This is significant as many GFP fusion proteins do not  
344 retain full functionality, as reported not only for Dpp-GFP but also for sarcomeric proteins  
345 such as Mhc-GFP, Sls-GFP or troponin-GFP fusion attempts (Matsuda et al., 2021; Orfanos  
346 et al., 2015; Sarov et al., 2016).

347 Nanobodies not only allow to monitor the dynamics of the target protein *in vivo*, as  
348 shown here for Sls, they can also be used to induce the degradation of the target protein, as  
349 shown for GFP-tagged proteins that can be degraded with the deGradFP system using a  
350 degradation box fused to the GFP nanobody (Caussinus et al., 2011; Nagarkar-Jaiswal et al.,  
351 2015). Nanobodies can also be useful as conditional blockers of their target domains, such as  
352 blocking a kinase domain as shown for EGFR in cell culture (Tabtimmai et al., 2019). Hence,

353 the here generated nanobody toolbox can be a first step towards modulation of Sls or Proj  
354 domains activity *in vivo*.

355 The small size of nanobodies not only allows superior penetration into tissues as  
356 shown here for late stage *Drosophila* embryos, but also places possible labels very close to  
357 their target epitopes. This is relevant for super-resolution microscopy that can resolve the  
358 target location with a precision better than 5 nm resolution (Schnitzbauer et al., 2017) or for  
359 cryo-electron-tomography, with which the native structure of titin in the sarcomere might be  
360 resolvable in the future (Wang et al., 2022; 2021). High labelling density and proximity of the  
361 label to the target are key to identify the nature of unknown protein densities in tomograms.  
362 Hence, our toolbox should not only provide a resource to mechanistically study the function  
363 of the *Drosophila* Sls and Proj proteins in more detail in the future but may also inspire the  
364 *Drosophila* community to invest more into the generation of nanobodies in future, instead of  
365 generating antibodies by default.

366

### 367 **A *Drosophila* titin nanobody toolbox**

368 We introduced here the generation and characterisation of 12 different nanobodies that were  
369 raised against 7 different target domains, 3 are present in Sls and 4 in Proj. We characterised  
370 their specificity in embryonic and larval muscles and verified that nanobodies are indeed well  
371 suited to diffuse into dense muscle tissues. They even label muscles of late stage embryos,  
372 which are impermeable to antibodies because of their chitin skeleton (Moussian, 2010).

373 Staining larval, leg and flight muscles with our nanobodies confirmed the existence of  
374 different Sls and Proj isoforms in the different muscle types. The stiff flight muscles do  
375 contain a short version of Sls, that does not allow to resolve the N- and C-terminal ends of Sls  
376 using confocal microscopy. This was only possible by using super-resolution microscopy with  
377 our here developed nanobodies (Schueder et al., 2022).

378 Our data suggest that most of the Sls isoforms present in flight muscles do contain the  
379 C-terminal Sls-Ig51-Fn2 domains. This is consistent with developmental transcriptomics  
380 results that included splice isoform annotations (Splinter et al., 2015; 2018), and the very low  
381 expression of a Sls isoform that uses an early alternative stop codon, which is rather expressed  
382 in leg muscles (Sarov et al., 2016). This is significant as the initially proposed short Sls  
383 isoform named Kettin is not supposed to contain the C-terminal Sls-Ig51-Fn2 domains and  
384 hence would not bridge across the thin I-band of flight muscles to the myosin filament  
385 (Burkart et al., 2007; Lakey et al., 1993; Szikora et al., 2020). Our new nanobodies now  
386 clarify that most Sls isoforms have at least the potential to bridge to the myosin filament in  
387 flight muscles (Schueder et al., 2022).

388 Similarly, our Proj nanobodies verified the defined orientation of Proj in flight muscle  
389 sarcomeres with its N-terminus facing the Z-disc and its C-terminal kinase domain oriented  
390 towards the center of myosin filament. In the accompanying manuscript these tools enabled  
391 the determination of the precise position of the Proj ends in the flight muscles using super-  
392 resolution microscopy (Schueder et al., 2022).

393

#### 394 **A long stretched Sls isoform in larval muscle**

395 Larval muscles are considered soft compared to stiff flight muscles. This is consistent with  
396 their large dynamic length range: larval sarcomeres have a relaxed length of about 8.5  $\mu\text{m}$  and  
397 can contract up to about 4.5  $\mu\text{m}$ . In contrast, flight muscle sarcomeres only contract 3.5% of  
398 their length during flight, about 120 nm (measured in *Drosophila virilis* (Chan and Dickinson,  
399 1996)). Consistently, the I-band of relaxed larval muscles is long, about 2  $\mu\text{m}$ . Hence, our  
400 finding that Sls has a length of more than 2  $\mu\text{m}$  in relaxed larval muscles is only logic,  
401 considering that Sls needs to elastically bridge from the Z-disc to the myosin filament.  
402 However, this finding still comes as a surprise, since the mammalian titin is considered to be  
403 the ‘longest’ protein in the animal kingdom, about 1.5  $\mu\text{m}$  long in 3  $\mu\text{m}$  long relaxed human

404 sarcomeres (Linke, 2018; Llewellyn et al., 2008; Regev et al., 2011). Mammalian titin is  
405 certainly the largest by molecular weight (up to 3800 kDa) (Brynnel et al., 2018), whereas the  
406 longest predicted *Drosophila* Sls isoform weights only 2100 kDa. Our data make it likely that  
407 *Drosophila* Sls is under strong molecular tension in larval muscles, however direct evidence  
408 by molecular tension measurements is still missing, and hence its long PEVK spring domains  
409 are likely unfolded to allow bridging of the long I-band in the relaxed state of the larval  
410 muscle (model in Figure 9). Such, Sls may store a significant amount of energy for the next  
411 round of muscle contraction, purely by unfolding its PEVK domains and not necessarily  
412 needing to unfold any of its Ig domains, which has recently been suggested for mammalian  
413 titin (Rivas-Pardo et al., 2016; 2020). Hence insect Sls might be the ‘longest’ protein naturally  
414 occurring in animals, a truly deserving member of the titin protein family.

415

#### 416 **A defined orientation of Projectin on myosin filaments**

417 In contrast to Sls, Proj does not locate in a sharp band in larval or leg muscles, but rather as a  
418 broad block, which had been previously reported (Lakey et al., 1990; Saide et al., 1989;  
419 Vigoreaux et al., 1991). Our data revealed that the N- and C-terminal ends of Proj display  
420 slightly shifted localisations, with the C-termini located closer the M-band compared to the N-  
421 termini. This strongly suggests that each Proj protein has a defined orientation on the myosin  
422 filament (model in Figure 9). Currently, it remains unclear if neighbouring Proj molecules  
423 overlap or if they are arrayed in a linear way to decorate the thick filament, similar to how the  
424 mammalian titin protein is supposed to decorate it (Tonino et al., 2017). Super-resolution  
425 imaging of larval muscles using our nanobodies will be needed to solve this interesting  
426 question.

427 The fact that Proj decorates the entire thick filament of likely all *Drosophila* muscles,  
428 except indirect flight muscles, has the interesting consequence that the Proj kinase is also  
429 located along the entire thick filament. Titin kinases including the Proj kinase are proposed to

430 be regulated by mechanical stretch: an inhibitory C-terminal tail needs to be pulled out of the  
431 kinase domain to allow kinase activity (Gautel, 2011; Gräter et al., 2005; Kobe et al., 1996;  
432 Lange et al., 2005). Thus, the larval muscle localisation of Proj would allow Proj to respond  
433 to stretch with kinase activation along the entire thick filament, and not only at the M-band as  
434 is the case for mammalian muscle. Hence, it will be interesting to resolve in the future if the  
435 kinase activity is required for sarcomere formation or function. The *Drosophila* larval  
436 muscles would be a good model to test this interesting question, and our here generated  
437 nanobodies, 4 of which target the Proj kinase domain might be a very valuable tool for these  
438 studies.

439 In summary, our *Drosophila* titin nanobody toolbox provides a rich resource for future  
440 studies of muscle development and maintenance in *Drosophila* and may also provide a  
441 paradigm for a strategy to investigate the molecular function and localisation of other large  
442 protein complexes during tissue morphogenesis.

443

444

445 **Methods**

446 *Recombinant immunogens and Nanobody generation*

447 We screened existing transcriptomics data (Spletter et al., 2015; 2018) and Flybase  
448 (<http://flybase.org/reports/FBgn0086906>; <http://flybase.org/reports/FBgn0005666>) to identify  
449 candidate domains of Sls and Proj that should be expressed in all muscle types. Next, we used  
450 Swissmodel (Waterhouse et al., 2018) to predict domain borders for stably folding fragments.  
451 These fragments were then codon-optimised for expression in *E.coli* and cloned into a His14-  
452 bdSUMO fusion vector (Frey and Görlich, 2014a). Expression was in *E.coli* NEB Express I<sup>q</sup>  
453 at 21°C, in 2YT + 50 µg/ml kanamycin with four hours of induction with 100 µM IPTG.  
454 Bacteria were pelleted by centrifugation, resuspended in 50 mM Tris/HCl pH 7.5, 20 mM  
455 imidazole/ HCl pH 7.5, 300 mM NaCl, lysed by a freeze-thaw cycle followed by sonication.  
456 The lysate was cleared by ultracentrifugation in a T645 rotor (Thermo) at 35.000 rpm for 90  
457 minutes. Purification by Ni(II) chelate capture and elution with 100 nM of the tag-cleaving  
458 bdSENP1 protease was as previously described (Frey and Görlich, 2014b). 100 µg of each  
459 antigen (in PBS) were used per immunisation with 200 µl Fama as an adjuvant (Gerbu #3030),  
460 following two pre-immunisations with myofibrils isolated from flight muscles of 500 adult  
461 flies.

462 Blood sampling, lymphocyte isolation, and construction of an M13 phage display  
463 library were done as described previously (Pleiner et al., 2015; 2018). Phage display itself  
464 was performed with 1 nM biotinylated baits immobilised to streptavidin magnetic beads.  
465 Selected clones were sequenced in a 96-well format. Coding sequences were cloned for  
466 expression into H<sub>14</sub>-NEDD8 or His<sub>14</sub>-ScSUMO vectors, with ectopic cysteines at N- and C-  
467 termini of the nanobody. The here described expression constructs will be made available at  
468 Addgene (<http://www.addgene.org>).

469

470 *Nanobody expression, purification, and labelling*

471 Nanobodies were expressed in NEB Shuffle Express, which allows the structural disulphide  
472 bond to be (partially) formed. Bacteria were grown initially in 5-liter flasks containing 250 ml  
473 TB medium supplemented with 50 µg/ml kanamycin and 0.5% glucose overnight at 37°C to  
474 stationary phase ( $OD_{600} \sim 10$ ). The cultures were then shifted to 21°C, diluted with 500 ml  
475 fresh medium, and induced 20 minutes later with 100 µM IPTG for 4 hours.

476 Bacteria were pelleted, resuspended in 50 ml sonication buffer (50 mM Tris/HCl pH  
477 7.5, 20 mM imidazole/ HCl pH 7.5, 300 mM NaCl, 5 mM GSH (reduced glutathione), 2.5  
478 mM GSSG (oxidised glutathione)). Lysis was done by one freeze-thaw cycle followed by  
479 sonication and ultracentrifugation as described above. The lysates were then either frozen in  
480 aliquots and stored at -80°C until further use or used directly for large-scale purification. For  
481 the latter, 30 ml of lysate were bound at 4°C to 2 ml Ni(II) matrix; the matrix was extensively  
482 washed with sonication buffer, followed by protease buffer (50 mM Tris/HCl pH 7.5, 20 mM  
483 imidazole/ HCl pH 7.5, 300 mM NaCl, 5 mM GSH, 5% w/v glycerol). Elution was done with  
484 50 nM ScUlp1 in protease buffer overnight at 4°C or for 2 hours at room temperature. Typical  
485 yields range between 10 to 50 mg nanobody per liter of culture.

486 For labelling, we used two different strategies. For in-solution-labelling, we reduced  
487 pre-purified nanobodies for 5 minutes with 20 mM DTT on ice. Then, free DTT was removed  
488 by gelfiltration on a Nap5 Sephadex G25 column (Cytiva) equilibrated and degassed in 50mM  
489 potassium phosphate pH 6.8, 300 mM NaCl, 1 mM imidazole (using a sample volume not  
490 exceeding 400 µl). Fluorophore-maleimides were dissolved to 10 mM in dimethylformamide,  
491 used in ~50% excess over cysteines to be labelled, pipetted into Eppendorf tubes (placed on  
492 ice) before the reduced nanobodies were added. The labelling reaction is fast and typically  
493 completed within a few minutes. Free fluorophore was then removed by gel filtration on a  
494 Nap5 column, equilibrated either in 50 mM Tris/ HCl pH7.5, 300 mM NaCl, 10% glycerol  
495 (for nanobodies with a negative net charge) or with 100 mM potassium phosphate pH 6.8, 10%

496 glycerol (for nanobodies with a positive net charge). For storage at 4°C, 0.05% sodium azide  
497 was added. Long-term storage was at -80°C.

498 Quality control was done by SDS-PAGE. For most fluorophores, unlabelled, single  
499 and double labelled nanobodies are well resolved, which allows assessing the completeness of  
500 the labelling reaction (see Figure 2A). Fluorescence images were acquired from  
501 unstained/unfixed gels with a Fuji FLA-9000 system. Concentrations of nanobody,  
502 fluorophore, and density of labelling (DOL) were measured photometrically at 280 nm and at  
503 the absorption maximum of the used fluorophore.  $\epsilon_{280}$  of the nanobody was deduced from its  
504 amino acid composition and used to calculate the protein concentration, also considering the  
505 cross-absorbance of the fluorophore at 280 nm. Extinction coefficients of the fluorophores at  
506 280 nm and the absorption maximum were taken from the respective suppliers.

507 Alternatively, nanobodies were labelled while bound as His<sub>14</sub>-ScSUMO or  
508 His<sub>14</sub>NEDD8 fusions to a Ni(II) chelate matrix. The matrix should be resistant to reduction by  
509 DTT. We used here a homemade matrix (Frey and Görlich, 2017), however, the cOmplete  
510 his-tag purification matrix from Roche is working equally well. In brief, 30 µl Ni beads were  
511 slightly overloaded with nanobody, typically by binding 650 µl lysate to them (this usually  
512 requires titration). The beads were then washed three times in 650 µl sonication buffer; the  
513 ectopic cysteines were reduced by a 5 minutes incubation at 0°C with 20 mM DTT, 50 mM  
514 Tris/HCl pH 7.5, 300 mM NaCl, 15 mM imidazole pH 7.5. The beads were then washed  
515 twice with degassed pre-labelling buffer (50 mM potassium phosphate pH 6.8, 15 mM  
516 imidazole/ HCl pH 7.0, 300 mM NaCl). 200 µl labelling solution (100-200 µM fluorophore in  
517 50 mM potassium phosphate pH 6.8, 1 mM imidazole/HCl pH 7.0, 300 mM NaCl) was added,  
518 the beads were shaken for 20 minutes at 0-4°C, washed twice in pre-labelling buffer, once in  
519 cleavage buffer (50 mM Tris/HCl pH 7.5, 500 mM NaCl, 20% glycerin), and finally eluted  
520 with 100 µl 50 nM ScUlp1 (in cleavage buffer) o/n at 4°C. The eluates typically contained  
521 100 µM labelled nanobody. 50 nM was typically used for stainings.

522

523 *Biolayer interferometry (BLI)*

524 BLI experiments were performed using High Precision Streptavidin biosensors and an Octet  
525 RED96e instrument (ForteBio/Sartorius) at 25°C with phosphate-buffered saline (PBS) pH  
526 7.4, 0.02% (w/v) Tween-20 and 0.1% (w/v) BSA as assay buffer. Sls-Nano2, modified via an  
527 N-terminal and a C-terminal ectopic cysteine with two Biotin-PEG<sub>3</sub>-Maleimide molecules  
528 (Iris Biotech), was bound at 0.6 µg/ml concentration to the sensors until a wavelength  
529 shift/binding signal of 0.4 nm was reached. After one washing step in buffer, the biosensors  
530 were dipped into wells containing a concentration series of the Sls-Ig13/14 domains to  
531 measure the association rate and then incubated with assay buffer for dissociation. Data were  
532 reference-subtracted, and curves were fitted globally with a 1:1 binding model (Octet Data  
533 Analysis HT 12.0 software).

534

535 *Myofibril isolation for immunisation*

536 We hand-dissected indirect flight muscles from 1000 adult wild-type flies from the Luminy  
537 strain (Leonte et al., 2021) in two batches of 500 each. To dissect, we cut away wings, head  
538 and abdomen and separated the thoraces into two halves along the midline using small  
539 dissection scissors (#15009-08 Fine Science Tools) and placed them into relaxing solution  
540 (100mM NaCl, 20mM NaPi pH7.2, 6mM MgCl<sub>2</sub>, 5mM ATP, 0.5% Triton X-100, complete  
541 protease inhibitor cocktail (Merck, Sigma #11697498001) with 50 % glycerol for a few  
542 minutes under the dissection scope. We then cut and scooped out the flight muscles, without  
543 taking gut or jump muscles using scissors and fine forceps (#11252-20 Dumont#5, Fine  
544 Science Tools). We collected flight muscles from 500 flies in one tube in relaxing buffer plus  
545 50% glycerol and left them up to 24h at -20°C. Then, we spun them down the myofibrils at  
546 200g and washed the pellet with relaxing buffer without glycerol. The purified myofibrils  
547 were then frozen in liquid nitrogen and stored at -80°C until used for alpaca immunisation.

548

549 *Fly strains and genetics*

550 Fly stocks were maintained under standard culture conditions (Avellaneda et al., 2021). All  
551 crosses were developed at 27 °C to enhance RNAi efficiency (Schnorrer et al., 2010). Wild-  
552 type control flies were *w[1118]* or *Mef2-GAL4* driver crossed to *w[1118]*. To knock-down *sls*  
553 or Projectin (*bt*) muscle-specific *Mef2-GAL4* was crossed with *UAS-sls-IR* (TF47301) or  
554 *UAS-bt-IR* (TF46252) long ds-RNAi lines obtained from the VDRC stock center (Dietzl et al.,  
555 2007) and embryonic muscles were stained with nanobodies.

556

557 *Embryo fixation and staining*

558 To investigate the larval musculature morphology at embryonic stages 16 and 17, crosses of  
559 the correct genotypes were set up in fly cages, in the presence of apple juice agar plates and a  
560 drop of yeast paste at 27°C. Flies were allowed to lay overnight and next day the embryos  
561 were collected and aged for at least another 8 h at 27°C. For fixation, embryos were  
562 dechorionated in 50% bleach for 2-3 min and then fixed for 20 min with a 1:1 mixture of 4%  
563 paraformaldehyde (PFA in fresh PBS) and heptane in glass tubes on shaker at room  
564 temperature. To free the embryos from the vitelline membrane, the fixative (lower phase) was  
565 removed with a glass pipette and one volume of methanol was added and the tube was shaken  
566 vigorously. Dechorionated embryos sunk to the bottom and were washed 3x with MeOH.  
567 Embryos were stored at -20°C in MeOH.

568 For antibody and nanobody stainings, embryos were rehydrated in PBST (PBS with  
569 0.3% Triton-X-100), blocked for more than 30 min with 4% normal goat serum and stained  
570 with fluorescently labelled nanobodies alone, or together with antibodies, overnight in PBST  
571 (PBS with 0.3% Triton-X-100). Antibodies were visualised with standard secondary  
572 antibodies (Molecular Probes, 1/500 in PBST) embryos were mounted in SlowFadeTM Gold

573 Antifade (Thermofisher) and imaged with a Zeiss LSM880 confocal microscope using a 40x  
574 objective.

575

576 *Flight and leg muscle staining*

577 Flight and leg muscles were stained as published in detail before (Weitkunat and Schnorrer,  
578 2014). Briefly, wings, head and abdomen were clipped from adult flies with fine scissors and  
579 thoraces were fixed in 4% PFA in PBS-T (PBS with 0.3% Triton X-100) for 20 min at room  
580 temperature. After washing once with PBST, the thoraces were placed on a slide with double-  
581 sticky tape with the head position facing the sticky tape and cut sagittally with a microtome  
582 blade (Pfm Medical Feather C35). Hemi-thoraces were stained with fluorescent nanobodies  
583 and rhodamine-phalloidin (1:1000 Molecular Probes) for 2 hrs at room temperature. Hemi-  
584 thoraces were washed twice with PBS-T, mounted in SlowFadeTM Gold Antifade  
585 (Thermofisher) using two cover slips as spacers and flight or leg muscles were imaged with a  
586 Zeiss LSM880 confocal microscope using 63x objective.

587

588 *Dissection and staining of larval muscles*

589 To perform antibody or nanobody stainings of larval muscles, third instar (L3) larvae were  
590 collected with a brush and placed at 4°C. For dissection, larvae were covered with HL3 buffer  
591 and pinned individually by pushing one insect pin through the head and one through the  
592 abdomen to immobilize them in dissection dishes placed on ice (Stewart et al., 1994). Pinned  
593 larvae were dissected with sharp scissors from the dorsal side in HL3 buffer and interior  
594 organs (gut and fat body) were removed with forceps. The remaining larval filets were fixed  
595 in 4% PFA in PBS-T (PBS with 0.3% Triton X-100) for 30 min, and then blocked in 4%  
596 normal goat serum for 30 min at room temperature (RT) on a shaker. Nanobodies and  
597 antibodies were incubated in PBS-T overnight at 4°C. Larval filets were then washed 3 times  
598 10 min in PBST at RT and stained with secondary antibodies and phalloidin (labelled with

599 rhodamine 1:1000, Molecular Probes) in PBST for 2 h, at RT in the dark. After washing 3  
600 times with PBST for 5 min, larval filets were mounted in SlowFadeTM Gold Antifade  
601 (Thermofisher) and imaged with a Zeiss LSM880 confocal microscope using 20x, 40x  
602 objectives.

603 To quantify larval sarcomere and Sls length, the images were processed with a  
604 Gaussian blur (sigma: 1.00) and a line perpendicular to the Z-disc was drawn to retrieve an  
605 intensity profile. The position of the peak of intensity was determined by using BAR plugin in  
606 Fiji (Schindelin et al., 2012). Sarcomere length was calculated by the distance between two  
607 peaks of Sls-Nano2 staining and Sls length by the distance between a peak of Sls-Nano2 and  
608 Sls-Nano42.

609

610 *Generation of UAS-Nano2-mNeonGreen transgenic flies*

611 To clone *UAS-Nano2-NeonGreen*, we first linearised pUAST-attB with EcoRI and inserted  
612 mNeonGreen by Gibson Assembly (Gibson Assembly®) after amplification of mNeonGreen  
613 with 5'-ACTCTGAATAGGAAATTGGGAATTC-3' and 5'-  
614 CGGCCGCAGATCTGTTAAC-3' primers. In a second step, we linearised pUAST-attB-  
615 mNeonGreen with EcoRI and inserted the Sls-Nano2 sequence by Gibson Assembly (Gibson  
616 Assembly®) after amplification with 5'- ACTCTGAATAGGAAATTGGG-3' and 5'-  
617 CCTTGCTCACCATGGAAC-3' primers. Finally, we inserted the pUAST-attB-Sls-Nano2-  
618 mNeonGreen plasmid at attP site VK00033 by standard injection and selection methods  
619 (Sarov et al., 2016).

620

621 *Live imaging of larval muscles*

622 To quantify Sls-Nano2 localisation *in vivo*, we crossed *UAS-Sls-Nano2-mNeonGreen* flies  
623 with *Mef2-GAL4* and collected L3 larvae. To reduce movement of the living larvae, larvae  
624 were anaesthetised for 5 min with diethylether (Aldrich) (Kakanj et al., 2020) and then

625 mounted in 10S halocarbon oil. Larvae were imaged with an Olympus spinning disc confocal  
626 microscope with a 60x objective. Photo-bleaching was performed with a 488 nm laser (Rapp-  
627 opto) and recovery was quantified during 30 min. Regions of interests (20 x 10  $\mu\text{m}$ ) inside the  
628 bleached area, in the non-bleached area or outside the muscle as background were selected  
629 and their intensities were measured at each time point. To calculate the ratio of FRAP the  
630 intensity of the bleached area background subtracted was divided by the intensity in the non-  
631 bleached area background subtracted.

632

633

634 **List of used antibodies and nanobodies**

<b>Antibodies</b>				
<b>clone name</b>	<b>antigene</b>	<b>species</b>	<b>dilution</b>	<b>origin/company</b>
3e8-3D3	Mhc	mouse	1/100	DHSB
MAC 155	Sls (Kettin)	rat	10/500	Babraham Institute
MAC 150	Projectin (bent)	rat	1/100	Babraham Institute

635

<b>Nanobodies</b>		
<b>Sls</b>	Sls-Nano2	A488; A647;
	Sls-Nano39	A488; A647;
	Sls-Nano42	A488; A647;
	Sls-Nano48	A488; A647;
<b>Proj (bt)</b>	Proj-Nano28	A488; A647;
	Proj-Nano29	A488; A647;
	Proj-Nano30	A488; A647;

Proj-Nano33	A488; A647;
Proj-Nano34	A488; A647;
Proj-Nano35	A488; A647;
Proj-Nano37	A488; A647;
Proj-Nano46	A488; A647;

636

637

638

639 **Acknowledgements**

640 We thank Stefan Raunser and Mathias Gautel and all their group members, as well as the  
641 Schnorrer and Görlich groups for their stimulating discussions within the  
642 StuDySARCOMERE ERC synergy grant. We thank Metin Aksu for help with the Octet  
643 measurements. We are grateful to the IBDM imaging facility for help with image acquisition  
644 and maintenance of the microscopes.

645

646 **Funding**

647 This work was supported by the Centre National de la Recherche Scientifique (CNRS, F.S.),  
648 the Max Planck Society (D. G.), Aix-Marseille University (P.M.), the European Research  
649 Council under the European Union's Horizon 2020 Programme (ERC-2019-SyG 856118 to  
650 D.G. & F.S.), the excellence initiative Aix-Marseille University A\*MIDEX (ANR-11-IDEX-  
651 0001-02, F.S.), the French National Research Agency with ANR-ACHN MUSCLE-FORCES  
652 (F.S.), the Human Frontiers Science Program (HFSP, RGP0052/2018, F.S.), the Bettencourt  
653 Foundation (F.S.), the France-BioImaging national research infrastructure (ANR-10-INBS-  
654 04-01) and the Investissements d'Avenir, French Government program managed by the  
655 French National Research Agency (ANR-16-CONV-0001) and from Excellence Initiative of

656 Aix-Marseille University - A\*MIDEX (Turing Center for Living Systems) and LabEx-  
657 INFORM (F.S. & V.L.).

658

659 The funders had no role in study design, data collection and analysis, decision to publish, or  
660 preparation of the manuscript.

661

662 **Competing interests**

663 The authors declare no competing interests.

664

665 **References**

666 Avellaneda, J., Rodier, C., Daian, F., Brouilly, N., Rival, T., Luis, N.M., and Schnorrer, F.  
667 (2021). Myofibril and mitochondria morphogenesis are coordinated by a mechanical feedback  
668 mechanism in muscle. *Nature Communications* 12, 2091–18.

669 Ayme-Southgate, A.J., Southgate, R.J., Philipp, R.A., Sotka, E.E., and Kramp, C. (2008). The  
670 myofibrillar protein, projectin, is highly conserved across insect evolution except for its  
671 PEVK domain. *Journal of Molecular Evolution* 67, 653–669.

672 Ákos, Z., Dunipace, L., and Stathopoulos, A. (2021). NaNuTrap: a technique for in vivo cell  
673 nucleus labelling using nanobodies. *Development* 148.

674 Brynnel, A., Hernandez, Y., Kiss, B., Lindqvist, J., Adler, M., Kolb, J., van der Pijl, R.,  
675 Gohlke, J., Strom, J., Smith, J., et al. (2018). Downsizing the molecular spring of the giant  
676 protein titin reveals that skeletal muscle titin determines passive stiffness and drives  
677 longitudinal hypertrophy. *eLife* 7, 1065.

678 Burkart, C., Qiu, F., Brendel, S., Benes, V., Hågg, P., Labeit, S., Leonard, K., and Bullard, B.  
679 (2007). Modular proteins from the *Drosophila* *sallimus* (*sls*) gene and their expression in  
680 muscles with different extensibility. *Journal of Molecular Biology* 367, 953–969.

681 Buszczak, M., Paterno, S., Lighthouse, D., Bachman, J., Planck, J., Owen, S., Skora, A.D.,  
682 Nystul, T.G., Ohlstein, B., Allen, A., et al. (2007). The carnegie protein trap library: a  
683 versatile tool for *Drosophila* developmental studies. *175*, 1505–1531.

684 Caussinus, E., Kanca, O., and Affolter, M. (2011). Fluorescent fusion protein knockout  
685 mediated by anti-GFP nanobody. *Nat. Struct. Mol. Biol.* 19, 117–121.

686 Chan, W.P., and Dickinson, M.H. (1996). In vivo length oscillations of indirect flight muscles  
687 in the fruit fly *Drosophila virilis*. *J Exp Biol* 199, 2767–2774.

688 Dietzl, G., Chen, D., Schnorrer, F., Su, K.-C., Barinova, Y., Fellner, M., Gasser, B., Kinsey,  
689 K., Oppel, S., Scheiblauer, S., et al. (2007). A genome-wide transgenic RNAi library for  
690 conditional gene inactivation in *Drosophila*. *Nature* *448*, 151–156.

691 Ferguson, C., Lakey, A., Hutchings, A., Butcher, G.W., Leonard, K.R., and Bullard, B. (1994).  
692 Cytoskeletal proteins of insect muscle: location of zeelins in *Lethocerus* flight and leg muscle.  
693 *Journal of Cell Science* *107* (Pt 5), 1115–1129.

694 Frey, S., and Görlich, D. (2014a). A new set of highly efficient, tag-cleaving proteases for  
695 purifying recombinant proteins. *J Chromatogr A* *1337*, 95–105.

696 Frey, S., and Görlich, D. (2014b). Purification of protein complexes of defined subunit  
697 stoichiometry using a set of orthogonal, tag-cleaving proteases. *J Chromatogr A* *1337*, 106–  
698 115.

699 Frey, S., and Görlich, D. (2017). Immobilization of chelating groups for immobilized metal  
700 ion chromatography (IMAC) -US Patent 9,675,960.

701 Fürst, D.O., Osborn, M., Nave, R., and Weber, K. (1988). The organization of titin filaments  
702 in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a  
703 map of ten nonrepetitive epitopes starting at the Z line extends close to the M line. *Journal of*  
704 *Cell Biology* *106*, 1563–1572.

705 Gautel, M. (2011). Cytoskeletal protein kinases: titin and its relations in mechanosensing.  
706 *Pflugers Arch - Eur J Physiol* *462*, 119–134.

707 González-Morales, N., Xiao, Y.S., Schilling, M.A., Marescal, O., Liao, K.A., and Schöck, F.  
708 (2019). Myofibril diameter is set by a finely tuned mechanism of protein oligomerization in  
709 *Drosophila*. *eLife* *8*.

710 Gräter, F., Shen, J., Jiang, H., Gautel, M., and Grubmüller, H. (2005). Mechanically induced  
711 titin kinase activation studied by force-probe molecular dynamics simulations. *Biophysj* *88*,  
712 790–804.

713 Harmansa, S., and Affolter, M. (2018). Protein binders and their applications in  
714 developmental biology. *Development* *145*.

715 Harmansa, S., Alborelli, I., Bieli, D., Caussinus, E., and Affolter, M. (2017). A nanobody-  
716 based toolset to investigate the role of protein localization and dispersal in *Drosophila*. *eLife* *6*.

717 Harmansa, S., Hamaratoglu, F., Affolter, M., and Caussinus, E. (2015). Dpp spreading is  
718 required for medial but not for lateral wing disc growth. *Nature* *527*, 317–322.

719 Kakanj, P., Eming, S.A., Partridge, L., and Leptin, M. (2020). Long-term in vivo imaging of  
720 *Drosophila* larvae. *Nat Protoc* *15*, 1158–1187.

721 Kanca, O., Bellen, H.J., and Schnorrer, F. (2017). Gene Tagging Strategies To Assess Protein  
722 Expression, Localization, and Function in *Drosophila*. *207*, 389–412.

723 Katzemich, A., Kreisköther, N., Alexandrovich, A., Elliott, C., Schöck, F., Leonard, K.,  
724 Sparrow, J., and Bullard, B. (2012). The function of the M-line protein obscurin in controlling  
725 the symmetry of the sarcomere in the flight muscle of *Drosophila*. *Journal of Cell Science* *125*,  
726 3367–3379.

727 Katzemich, A., Liao, K.A., Czerniecki, S., and Schöck, F. (2013). Alp/Enigma family  
728 proteins cooperate in Z-disc formation and myofibril assembly. *PLoS Genetics* 9, e1003342.

729 Katzemich, A., West, R.J.H., Fukuzawa, A., Sweeney, S.T., Gautel, M., Sparrow, J., and  
730 Bullard, B. (2015). Binding partners of the kinase domains in *Drosophila obscurin* and their  
731 effect on the structure of the flight muscle. *Journal of Cell Science* 128, 3386–3397.

732 Kelso, R.J., Buszczak, M., Quiñones, A.T., Castiblanco, C., Mazzalupo, S., and Cooley, L.  
733 (2004). Flytrap, a database documenting a GFP protein-trap insertion screen in *Drosophila*  
734 *melanogaster*. *Nucleic Acids Res.* 32, D418–D420.

735 Kobe, B., Heierhorst, J., Feil, S.C., Parker, M.W., Benian, G.M., Weiss, K.R., and Kemp, B.E.  
736 (1996). Giant protein kinases: domain interactions and structural basis of autoregulation. *The*  
737 *EMBO Journal* 15, 6810–6821.

738 Kulke, M., Neagoe, C., Kolmerer, B., Minajeva, A., Hinssen, H., Bullard, B., and Linke, W.A.  
739 (2001). Kettin, a major source of myofibrillar stiffness in *Drosophila* indirect flight muscle.  
740 *Journal of Cell Biology* 154, 1045–1057.

741 Lakey, A., Ferguson, C., Labeit, S., Reedy, M., Larkins, A., Butcher, G., Leonard, K., and  
742 Bullard, B. (1990). Identification and localization of high molecular weight proteins in insect  
743 flight and leg muscle. *The EMBO Journal* 9, 3459–3467.

744 Lakey, A., Labeit, S., Gautel, M., Ferguson, C., Barlow, D.P., Leonard, K., and Bullard, B.  
745 (1993). Kettin, a large modular protein in the Z-disc of insect muscles. *The EMBO Journal* 12,  
746 2863–2871.

747 Lange, S., Ehler, E., and Gautel, M. (2006). From A to Z and back? Multicompartment  
748 proteins in the sarcomere. *Trends in Cell Biology* 16, 11–18.

749 Lange, S., Xiang, F., Yakovenko, A., Vihola, A., Hackman, P., Rostkova, E., Kristensen, J.,  
750 Brandmeier, B., Franzen, G., Hedberg, B., et al. (2005). The kinase domain of titin controls  
751 muscle gene expression and protein turnover. *Science* 308, 1599–1603.

752 Lemke, S.B., and Schnorrer, F. (2017). Mechanical forces during muscle development.  
753 *Mechanisms of Development* 144, 92–101.

754 Leonte, M.-B., Leonhardt, A., Borst, A., and Mauss, A.S. (2021). Aerial course stabilization  
755 is impaired in motion-blind flies. *Journal of Experimental Biology* 224.

756 Linke, W.A. (2018). Titin Gene and Protein Functions in Passive and Active Muscle. *Annu.*  
757 *Rev. Physiol.* 80, 389–411.

758 Llewellyn, M.E., Barreto, R.P.J., Delp, S.L., and Schnitzer, M.J. (2008). Minimally invasive  
759 high-speed imaging of sarcomere contractile dynamics in mice and humans. *Nature* 454, 784–  
760 788.

761 Luis, N.M., and Schnorrer, F. (2021). Mechanobiology of muscle and myofibril  
762 morphogenesis. *Cells & Development* 203760.

763 Matsuda, S., Schaefer, J.V., Mii, Y., Hori, Y., Bieli, D., Taira, M., Plückthun, A., and Affolter,  
764 M. (2021). Asymmetric requirement of Dpp/BMP morphogen dispersal in the *Drosophila*  
765 wing disc. *Nature Communications* 12, 6435–18.

766 Moussian, B. (2010). Recent advances in understanding mechanisms of insect cuticle  
767 differentiation. *Insect Biochem. Mol. Biol.* *40*, 363–375.

768 Muyldermans, S. (2013). Nanobodies: natural single-domain antibodies. *Annu. Rev. Biochem.*  
769 *82*, 775–797.

770 Nagarkar-Jaiswal, S., Nagarkar-Jaiswal, S., Lee, P.-T., Lee, P.-T., Campbell, M.E., Campbell,  
771 M.E., Chen, K., Anguiano-Zarate, S., Anguiano-Zarate, S., Gutierrez, M.C., et al. (2015). A  
772 library of MiMICs allows tagging of genes and reversible, spatial and temporal knockdown of  
773 proteins in *Drosophila*. *eLife* *4*, 2743.

774 O'Donnell, P.T., Collier, V.L., Mogami, K., and Bernstein, S.I. (1989). Ultrastructural and  
775 molecular analyses of homozygous-viable *Drosophila melanogaster* muscle mutants indicate  
776 there is a complex pattern of myosin heavy-chain isoform distribution. *Genes & Development*  
777 *3*, 1233–1246.

778 Orfanos, Z., and Sparrow, J.C. (2013). Myosin isoform switching during assembly of the  
779 *Drosophila* flight muscle thick filament lattice. *Journal of Cell Science* *126*, 139–148.

780 Orfanos, Z., Leonard, K., Elliott, C., Katzemich, A., Bullard, B., and Sparrow, J. (2015).  
781 Sallimus and the dynamics of sarcomere assembly in *Drosophila* flight muscles. *Journal of  
782 Molecular Biology* *427*, 2151–2158.

783 Pleiner, T., Bates, M., and Görlich, D. (2018). A toolbox of anti-mouse and anti-rabbit IgG  
784 secondary nanobodies. *The Journal of Cell Biology* *217*, 1143–1154.

785 Pleiner, T., Bates, M., Trakhanov, S., Lee, C.-T., Schliep, J.E., Chug, H., Böhning, M., Stark,  
786 H., Urlaub, H., and Görlich, D. (2015). Nanobodies: site-specific labeling for super-resolution  
787 imaging, rapid epitope-mapping and native protein complex isolation. *eLife* *4*, e11349.

788 Qiu, F., Brendel, S., Cunha, P., Astola, N., Song, B., Furlong, E., Leonard, K., and Bullard, B.  
789 (2005). Myofilin, a protein in the thick filaments of insect muscle. *Journal of Cell Science* *118*,  
790 1527.

791 Regev, G.J., Kim, C.W., Tomiya, A., Lee, Y.P., Ghofrani, H., Garfin, S.R., Lieber, R.L., and  
792 Ward, S.R. (2011). Psoas Muscle Architectural Design, In Vivo Sarcomere Length Range,  
793 and Passive Tensile Properties Support Its Role as a Lumbar Spine Stabilizer. *Spine* *36*,  
794 E1666–E1674.

795 Rivas-Pardo, J.A., Eckels, E.C., Popa, I., Kosuri, P., Linke, W.A., and Fernandez, J.M. (2016).  
796 Work Done by Titin Protein Folding Assists Muscle Contraction. *Cell Reports* *14*, 1339–1347.

797 Rivas-Pardo, J.A., Li, Y., Mártonfalvi, Z., Tapia-Rojo, R., Unger, A., Fernández-Trasancos,  
798 Á., Herrero-Galán, E., Velázquez-Carreras, D., Fernandez, J.M., Linke, W.A., et al. (2020). A  
799 HaloTag-TEV genetic cassette for mechanical phenotyping of proteins from tissues. *Nature  
800 Communications* *11*, 2060–13.

801 Saide, J., Chin-Bow, S., Hogan-Sheldon, J., Busquets-Turner, L., Vigoreaux, J., Valgeirsdottir,  
802 K., and Pardue, M. (1989). Characterization of components of Z-bands in the fibrillar flight  
803 muscle of *Drosophila melanogaster*. *Journal of Cell Biology* *109*, 2157.

804 Sarov, M., Barz, C., Jambor, H., Hein, M.Y., Schmied, C., Suchold, D., Stender, B., Janosch, S., K J, V.V., Krishnan, R.T., et al. (2016). A genome-wide resource for the analysis of protein localisation in *Drosophila*. *eLife* 5, e12068.

805

806

807 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nature Methods* 9, 676–682.

808

809

810 Schnitzbauer, J., Strauss, M.T., Schlichthaerle, T., Schueder, F., and Jungmann, R. (2017). Super-resolution microscopy with DNA-PAINT. *Nat Protoc* 12, 1198–1228.

811

812 Schnorrer, F., Schönauer, C., Langer, C.C.H., Dietzl, G., Novatchkova, M., Schernhuber, K., Fellner, M., Azaryan, A., Radolf, M., Stark, A., et al. (2010). Systematic genetic analysis of muscle morphogenesis and function in *Drosophila*. *Nature* 464, 287–291.

813

814

815 Schönauer, C., Distler, J., Jährling, N., Radolf, M., Dodt, H.-U., Frasch, M., and Schnorrer, F. (2011). Spalt mediates an evolutionarily conserved switch to fibrillar muscle fate in insects. *Nature* 479, 406–409.

816

817

818 Schueder, F., Mangeol, P., Chan, E.H., Rees, R., Schünemann, J., Görlich, D., Jungmann, R., and Schnorrer, F. (2022). Nanobodies combined with DNA-PAINT super-resolution reveal a staggered titin nano-architecture in flight muscles. *bioRxiv*.

819

820

821 Spletter, M.L., and Schnorrer, F. (2014). Transcriptional regulation and alternative splicing cooperate in muscle fiber-type specification in flies and mammals. *Experimental Cell Research* 321, 90–98.

822

823

824 Spletter, M.L., Barz, C., Yeroslaviz, A., Schönauer, C., Ferreira, I.R.S., Sarov, M., Gerlach, D., Stark, A., Habermann, B.H., and Schnorrer, F. (2015). The RNA-binding protein Arrest (Bruno) regulates alternative splicing to enable myofibril maturation in *Drosophila* flight muscle. *EMBO Rep* 16, 178–191.

825

826

827

828 Spletter, M.L., Barz, C., Yeroslaviz, A., Zhang, X., Lemke, S.B., Bonnard, A., Brunner, E., Cardone, G., Basler, K., Habermann, B.H., et al. (2018). A transcriptomics resource reveals a transcriptional transition during ordered sarcomere morphogenesis in flight muscle. *eLife* 7, 1361.

829

830

831

832 Stewart, B.A., Atwood, H.L., Renger, J.J., Wang, J., and Wu, C.F. (1994). Improved stability of *Drosophila* larval neuromuscular preparations in haemolymph-like physiological solutions. *J Comp Physiol A* 175, 179–191.

833

834

835 Szikora, S., Gajdos, T., Novák, T., Farkas, D., Földi, I., Lenart, P., Erdélyi, M., and Mihály, J. (2020). Nanoscopy reveals the layered organization of the sarcomeric H-zone and I-band complexes. *The Journal of Cell Biology* 219.

836

837

838 Tabtimmai, L., Suphakun, P., Srisook, P., Kiriwan, D., Phanthong, S., Kiatwuthinon, P., Chaicumpa, W., and Choowongkomon, K. (2019). Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. *Journal of Cellular Biochemistry* 120, 18077–18087.

839

840

841

842

843 Tonino, P., Kiss, B., Strom, J., Methawasin, M., Smith, J.E., Kolb, J., Labeit, S., and Granzier,  
844 H. (2017). The giant protein titin regulates the length of the striated muscle thick filament.  
845 *Nature Communications* 8, 1041.

846 Tskhovrebova, L., and Trinick, J. (2003). Titin: properties and family relationships. *Nature*  
847 *Reviews Molecular Cell Biology* 4, 679–689.

848 Vigoreaux, J.O., Saide, J.D., and Pardue, M.L. (1991). Structurally different Drosophila  
849 striated muscles utilize distinct variants of Z-band-associated proteins. *J Muscle Res Cell*  
850 *Motil* 12, 340–354.

851 Wang, Z., Grange, M., Pospich, S., Wagner, T., Kho, A.L., Gautel, M., and Raunser, S.  
852 (2022). Structures from intact myofibrils reveal mechanism of thin filament regulation  
853 through nebulin. *Science* 375, eabn1934.

854 Wang, Z., Grange, M., Wagner, T., Kho, A.L., Gautel, M., and Raunser, S. (2021). The  
855 molecular basis for sarcomere organization in vertebrate skeletal muscle. *Cell* 184, 2135–  
856 2150.e13.

857 Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T.,  
858 de Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: homology  
859 modelling of protein structures and complexes. *Nucleic Acids Res.* 46, W296–W303.

860 Weitkunat, M., and Schnorrer, F. (2014). A guide to study Drosophila muscle biology.  
861 *Methods* 68, 2–14.

862 Weitkunat, M., Brasse, M., Bausch, A.R., and Schnorrer, F. (2017). Mechanical tension and  
863 spontaneous muscle twitching precede the formation of cross-striated muscle *in vivo*.  
864 *Development* 144, 1261–1272.

865 Weitkunat, M., Kaya-Copur, A., Grill, S.W., and Schnorrer, F. (2014). Tension and force-  
866 resistant attachment are essential for myofibrillogenesis in Drosophila flight muscle. *Curr*  
867 *Biol* 24, 705–716.

868 Xu, J., Kim, A.-R., Cheloha, R.W., Fischer, F.A., Li, J.S.S., Feng, Y., Stoneburner, E., Binari,  
869 R., Mohr, S.E., Zirin, J., et al. (2022). Protein visualization and manipulation in Drosophila  
870 through the use of epitope tags recognized by nanobodies. *eLife* 11.

871

872

873 **Figure legends**

874 **Figure 1 – *Drosophila* titin nanobody design. (A, B)** Schematic of Sallimus (A) and  
875 Projectin (B) gene and protein domain organisation. Top: genome loci taken from Flybase  
876 with exons represented by magenta arrows and introns by lines. The coded protein domains  
877 are overlayed with Ig-domains in brown, PEVK in orange, Fn- and kinase domains in green.  
878 Bottom: predicted domain organisation of Sls long and short (internal STOP) and Proj long  
879 larval muscle protein isoforms. Domains selected for nanobody production are highlighted by  
880 special colours and the names of the respective nanobodies are indicated above the protein.

881

882 **Figure 2 – Nanobody production pipeline.** Overview of our optimised nanobody production  
883 pipeline against *Drosophila* sarcomeric protein domains. See text for details. Scale bar is 3  
884  $\mu\text{m}$ .

885

886 **Figure 3 – Nanobody labelling and affinity test. (A)** SDS-PAGE gel documenting the  
887 expression, purification, tag cleavage and labelling of a nanobody, here Sls-Nano2. Top part  
888 stained with Coomassie blue, lower part shows fluorescence of the same gel. Note the  
889 efficiency of the labelling (essentially quantitative) by the size shift of the bands. **(B)**  
890 Nanobody affinity assay. Sls-Nano2-biotin was immobilised to high precision streptavidin  
891 Octet sensors to a binding signal of 0.4 nm. After washing, the target domain Sls-Ig13/14 was  
892 allowed to bind at indicated concentration for 200 seconds (beige box), followed by a 900  
893 seconds dissociation step. A global fit of the curves indicates a 10 pM  $K_D$ .

894

895 **Figure 4 – Sallimus and Projectin nanobody specificity**

896 **(A, B)** top: schematic representation of Sallimus or Projectin domains with nanobodies used  
897 for stainings. Bottom: stage 17 embryos of wild type (*Mef2-GAL4*) and muscle specific *sls* or  
898 *bt* knock-down (*Mef2-GAL4*, UAS-*sls-IR* and *Mef2-GAL4*, UAS-*bt-IR*, respectively) stained

899 with Sls (green) and Proj (magenta) nanobodies Sls-Nano2 and Proj-Nano28 (A) or Sls-  
900 Nano42 and Proj-Nano30 (B). Note the striated pattern of Sls and Proj in wild type, which is  
901 lost upon knock-down of one component. Scale bars are 20  $\mu$ m.

902

903 **Figure 5 – Nanobodies penetrate embryos easier than antibodies.**

904 (A-C) Stage 16 and 17 wild type embryos (*Mef2-GAL4*) stained with Sls and Proj nanobodies  
905 (Sls-Nano2, Proj-Nano28, Proj-Nano30) in green, in combination with antibodies against Sls  
906 (anti-Kettin) (A), Mhc (B) or Projectin (C) in magenta. Scale bar 20  $\mu$ m. Note that Sls, Mhc  
907 and Proj antibodies cannot penetrate into stage 17 embryos efficiently, whereas the respective  
908 nanobodies stain muscles well.

909

910 **Figure 6 – Sallimus and Projectin localisation in mature sarcomeres.**

911 (A-C) Mature sarcomeres from wild type flight muscles (A), leg muscles (B) or L3 larval  
912 muscles (C) stained by phalloidin (actin) together with N- and C-terminal Sls nanobodies  
913 (Sls-Nano2 in green and Sls-Nano42 in magenta, top) or N- and C-terminal Proj nanobodies  
914 (Proj-Nano30 in green and Proj-Nano37 in magenta, bottom). Scale bars are 3  $\mu$ m. Note the  
915 long distance between the Sls-Nano42 bands in larval muscles and the distinct locations of  
916 Proj-Nano30 and Proj-Nano37 in leg and larval muscles.

917

918 **Figure 7 – Sallimus and Projectin localisation in mature larval muscles**

919 (A) L3 larval muscles stained for actin, as well as N-(Sls-Nano2, green) and C-terminal (Sls-  
920 Nano42, magenta) Sls nanobodies. Scale bar 3  $\mu$ m. Plot displays longitudinal intensity profile  
921 of Sls-Nano2 and Sls-Nano42. Quantification of sarcomere length (distance between Sls-  
922 Nano2 bands) and Sls length (distance between Sls-Nano2 and Sls-Nano42). Each point  
923 represents an animal, n = 10. (B) L3 larval muscle stained for myosin (green), N-(Sls-Nano2)  
924 and C-terminal (Sls-Nano42, magenta) Sls nanobodies. Scale bar 3  $\mu$ m. Plot displays intensity

925 profile of myosin and Sls-Nano42. Note that peaks of Nano42 map to the start of the myosin  
926 signal. **(C)** L3 larval muscle stained for Projectin with N-(Proj-Nano30, green) and C-terminal  
927 (Proj-Nano37, magenta) nanobodies and imaged with the airy-scan detector. Scale bar 3 $\mu$ m.  
928 Plot displays intensity profile of Proj-Nano30 and Proj-Nano37. Note that the Proj-Nano37  
929 signal closer to the M-Band. **(D)** Obscurin GFP larvae stained for Projectin with N-(Proj-  
930 Nano30) or C-terminal (Proj-Nano37) nanobodies and imaged with an airy scan detector.  
931 Scale bar 3 $\mu$ m. Plots display intensity profiles. Note that Obscurin perfectly fills the Proj-  
932 Nano37 gap at the M-band.

933

934 **Figure 8 – Live imaging of Sls using nanobodies *in vivo***

935 **(A)** Living L3 larval muscles expressing Sls-Nano2-Neongreen driven with *Mef2-GAL4*.  
936 Note the striated pattern marking the Z-disc. A region marked by the red rectangle was  
937 bleached (the larvae was slightly moving while being bleached) and fluorescence recovery  
938 was imaged. A single z-plane of a stack is shown. **(B)** Quantification of fluorescence recovery  
939 in the orange box, which was normalised by the fluorescence in the yellow box outside the  
940 bleached area. The different grey values indicate four different larvae from four different  
941 experiments. Note either absence or less than 20% recovery in the bleached area over 30  
942 minutes.

943

944 **Figure 9 – Hypothetical model of a larval sarcomere**

945 Cartoon model of Sallimus and Projectin arrangements in a larval sarcomere. Our data reveal  
946 the polar orientation of Projectin on the myosin filament however, the precise arrangement of  
947 the individual molecules remains to be determined.

948 **Supplementary figures legends**

949 **Figure 4 – figure supplement 1**

950 **(A, B)** top: schematic representation of Sallimus or Projectin domains with nanobodies used  
951 for stainings. Bottom: stage 17 embryos of wild type (*Mef2-GAL4*) and muscle specific *sls* or  
952 *bt* knock-down (*Mef2-GAL4*, UAS-*sls-IR* and *Mef2-GAL4*, UAS-*bt-IR*, respectively) stained  
953 with Sls (green) and Proj (magenta) nanobodies Sls-Nano2 and Proj-Nano30 (A) or Sls-  
954 Nano39 and Proj-Nano34 (B). Note the striated pattern of Sls and Proj in wild type, which is  
955 lost upon knock-down of one component. Scale bars are 20  $\mu$ m.

956

957 **Figure 4 – figure supplement 2**

958 **(A, B)** top: schematic representation of Sallimus or Projectin domains with nanobodies used  
959 for stainings. Bottom: stage 17 embryos of wild type (*Mef2-GAL4*) and muscle specific *sls* or  
960 *bt* knock-down (*Mef2-GAL4*, UAS-*sls-IR* and *Mef2-GAL4*, UAS-*bt-IR*, respectively) stained  
961 with Sls (green) and Proj (magenta) nanobodies Sls-Nano2 and Proj-Nano29 (A) or Sls-  
962 Nano48 and Proj-Nano33 (B). Note the striated pattern of Sls and Proj in wild type, which is  
963 lost upon knock-down of one component. Scale bars are 20  $\mu$ m.

964

965 **Figure 7 – figure supplement 1**

966 **(A)** Wild type L3 larval muscle stained for actin and Sallimus with N-(Sls-Nano2, green) and  
967 C-terminal (Sls-Nano39, magenta) Sls nanobodies. Note the large distance of the Sls-Nano39  
968 bands (a central SlsNano39 band at the Z-disc is sometimes seen that may indicate  
969 mechanical detachment of Sls during the muscle preparation). **(B)** Wild type L3 larval muscle  
970 stained for actin, myosin and Projectin with N-(Proj-Nano28, green) and C-terminal (Proj-  
971 Nano34, magenta) nanobodies. Note the shift of N- versus C-terminal nanobodies, both label  
972 the myosin filament. **C)** Wild type L3 larval muscle stained for actin and Projectin with N-  
973 (Proj-Nano29, green) and C-terminal (Proj-Nano35, magenta) nanobodies. **(D)** Wild type L3

974 larval muscle stained for actin and Projectin with N-(Proj-Nano29, green) and C-terminal  
975 (Proj-Nano33, magenta) nanobodies. **(E, F)** Wild type L3 larval muscle stained for actin and  
976 Projectin with two N-terminal (Proj-Nano30, green and Proj-nano28, magenta, in E) or two  
977 C-terminal (Proj-Nano35, green and Proj-Nano46, magenta in F) nanobodies. Note that the  
978 two N-terminal or C-terminal nanobody patterns overlap. Scale bars are 3  $\mu$ m.


979

980


981 **Figure 8 – video 1. Live imaging of Sls with a nanobody using FRAP**

982 Living L3 larva expressing Sls-Nano2-Neongreen was imaged with a spinning disc confocal.  
983 One single plane is shown and assembled into the movie. The white square after the pre-  
984 bleach frames indicates the bleached area. One z-stack was recorded each minute after  
985 bleaching for 30 min, from which one frame is shown. Note that the larva is moving slightly  
986 during the experiment. There is little recovery of Sls-Nano2-Neongreen in the bleached area  
987 over a 30 min period.

988



**B Projectin domains and nanobody design**



**Figure 1**

## anti *Drosophila* protein nanobody production pipeline

### 1. Immunogen preparation

- a) *Drosophila* flight muscle dissection and myofibril isolation
- b) recombinant antigen production



### 2. Alpaca immunisation

- a) two immunisations with dissected myofibrils
- b) three additional immunisations with purified proteins



### 3. Nanobody library and selection

- a) construction of immune library
- b) phage display with immobilised target protein
- c) sequencing and clone selection



### 4. Nanobody labelling and purification

- a) nanobody expression in *E. coli* and purification
- b) nanobody conjugation with fluorescent dyes or biotin
- c) affinity test against recombinant target protein



### 5. Nanobody staining of *Drosophila* larval muscles








Figure 2

**A****Nanobody purification and labelling**

bioRxiv preprint doi: <https://doi.org/10.1101/2022.04.13.488177>; this version posted April 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

**B****Nanobody affinity for target domain****Figure 3**



**Figure 4**





Figure 4 - figure supplement 1












Figure 4 - figure supplement 2




**Figure 5**


**A****B****C****Figure 6**

**A****length of Sallimus in larval muscle****B****Sallimus and Myosin in larval muscle****C****Projectin N- and C-terms in larval muscle****D****C-term of Projectin and M-band Obscurin in larval muscle****Figure 7**


**A**




**B**




**C**




**D**



**E**





**F**



**Figure 7 - figure supplement 1**

**A****Sls-Nano2 recovery in living muscle**

bioRxiv preprint doi: <https://doi.org/10.1101/2022.04.13.488177>; this version posted April 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [aCC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

**B****FRAP quantification****Figure 8**

### Molecular model of a larval sarcomere




Figure 9